World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT02728271
Date of registration: 14/03/2016
Prospective Registration: Yes
Primary sponsor: Mounzer Agha
Public title: Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
Scientific title: A Pilot Study of Immuno-ablation With Chemoimmunoradiation Followed by Autologous Hematopoietic Progenitor Cell (HPC) Transplant for Adult Subjects With Churg-Strauss Syndrome
Date of first enrolment: April 2016
Target sample size: 1
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT02728271
Study type:  Interventional
Study design:  Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Early Phase 1
Countries of recruitment
Contacts
Name:     Mounzer Agha, MD
Address: 
Telephone:
Email:
Affiliation:  University of Pittsburgh
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age 18-60, inclusive

- Subjects carry a diagnosis of Churg-Strauss syndrome, with typical clinical,
pathologic, and/or radiological appearances.

- Must have a pulmonologist/immunologist providing the primary care for the
Churg-Strauss syndrome and be willing to be evaluated for the Churg-Strauss syndrome
who is the co-investigator in the protocol.

- Must be documented to be HIV negative.

- Subjects must be able to give written consent.

- Subjects with abscesses are eligible to enroll once the abscesses or any other
significant infection has resolved.

- Subjects must not be pregnant and will undergo a pregnancy test prior to starting the
study treatment. The subjects should also be willing to take the appropriate
contraception starting at least three months prior to the transplant.

- All eligible subjects will need the approval of the insurance company for the coverage
of the study treatment.

- Life expectancy of more than 6 months. ECOG performance status of 0 or 1.

- No evidence of myelodysplastic on peripheral blood smear

- Baseline serum creatinine must be <1.5 mg/dL, left ventricular ejection fraction >55%,
adequate pulmonary functions (oxygen saturation at room air of >90%), and AST and ALT
not > 2x upper limits of normal, and no history of previous or active malignancy,
except for localized cutaneous basal or squamous cell carcinoma in situ of the cervix.

- Evidence for life threatening disease, including FEV1 <50% predicted (on therapy)
and/or cardiac involvement (arrhythmias, failure)

- Failure to stabilize in response to prednisone (or equivalent) at doses of <20 mg per
day

- Failure of at least 3 other immunosuppressives to stabilize disease, including drugs
like cyclophosphamide, rituximab, mepolizumab, azathioprine.

Exclusion Criteria:

- Failure to accept or comprehend irreversible sterility as a potential side effect of
therapy.

- Previous allergy to cyclophosphamide, rituximab, mepolizumab, azathioprine.



Age minimum: 18 Years
Age maximum: 60 Years
Gender: All
Health Condition(s) or Problem(s) studied
Churg-Strauss Syndrome
Intervention(s)
Biological: HPC cell infusion
Primary Outcome(s)
number of patients with adverse events during treatment [Time Frame: change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, 42, 48 months and then every 12 months, up to 100 months or if the patient dies, whichever occurs first.]
Secondary Outcome(s)
graft failure rate [Time Frame: change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, 42, 48 months and then every 12 months, up to 100 months or until the patient dies, whichever occurs first.]
hematologic recovery [Time Frame: change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, 42, 48 months and then every 12 months, up to 100 months or until the patient dies, whichever occurs first.]
resolution of eosinophilia [Time Frame: change from baseline at 3, 6, 9, 12, 18, 24, 30, 36, 42, 48 months and then every 12 months, up to 100 months or until the patient dies, whichever occurs first.]
Secondary ID(s)
15-146
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history